Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Newron Pharmaceuticals
Newron Pharmaceuticals
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Safinamide to be made available in Asia for Parkinson's
Meiji Seika and Eisai enter into a collaboration for the development and commercialisation of safinamide in Parkinson’s disease for Japan and Asia
FDA approves Xadago for Parkinson’s patients
Xadago (safinamide) is first NCE approved in the USA for PD patients with motor fluctuations in a decade
Pharmaceutical
Newron starts operations in New Jersey, US
Two senior executives join the company and will be located in Morristown, New Jersey
Regulatory
Parkinson’s disease – safinamide
The effectiveness of dopamine agonist drugs to treat Parkinson\'s disease decreases over time as more and more dopamine-producing cells die
Research & Development
Newron receives €2.5m grant from Wellcome Trust
To fund clinical trial for amyotrophic lateral sclerosis (ALS)
Finance
Newron to acquire NeuroNova for €15.4m
Gains two Phase II compounds for progressive neurogenerative diseases
Research & Development
Newron and Zambon enter into a new €5m agreement for safinamide
Zambon will make a total investment in Newron of €20m
Subscribe now